Description
Ponatinib is a multi-targeted tyrosine kinase inhibitor that is active against T315I and other BCR-Abl mutants. It inhibits all tested BCR-Abl mutants in cellular and biochemical assays, suppresses BCR-Abl(T315I)-driven tumor growth in mice, and completely abrogates resistance in cell-based mutagenesis screens.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that is active against T315I and other BCR-Abl mutants. It inhibits all tested BCR-Abl mutants in cellular and biochemical assays, suppresses BCR-Abl(T315I)-driven tumor growth in mice, and completely abrogates resistance in cell-based mutagenesis screens.
Alternate Name/Synonyms: 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide; AP24534
Appearance: White solid
Formulation: N/A
CAS Number: 943319-70-8
Structure Available?: Y
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₉H₂₇F₃N₆O
Molecular Weight: 532.56
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (~50 mg/ml) or EtOH (~ 25 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent multi-kinase and pan-BCR-Abl inhibitor.
MDL Number: MFCD17215203
PubChem CID: 24826799
SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
InChi: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
InChi Key: PHXJVRSECIGDHY-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |